Department of Dermatology, Institute of Dermatology, Peking University Shenzhen Hospital, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen, China.
Department of Epidemiology, School of Public Health, Fudan University, Shanghai, China
BMJ Open. 2022 Jan 7;12(1):e053488. doi: 10.1136/bmjopen-2021-053488.
Atopic dermatitis (AD) is a chronic inflammatory skin disease and skin microbiota dysbiosis shows an important role in the pathogenesis of AD. Effects of treatment on skin microbiota for patients with AD have been evaluated in recent years; however, the results remained controversial across studies. This systematic review will summarise studies evaluating the effect of treatments on skin microbiota among patients with AD.
We will search PubMed, EMBASE, Web of Science, ClinicalTrials.gov and Chinese Clinical Trial Registry in November 2021; other data sources will also be considered, including searching specific authors and screening references cited in the enrolled articles. Interventional studies, which enrolled patients with AD receiving treatments and reported treatment-related skin microbiota changes, will be included. Our primary outcomes include skin microbiota diversity and treatment-related differential microbes; the secondary outcomes include microbiota functions and microbial interactions. Risk of bias assessment will be performed using Cochrane risk-of-bias tool for randomised trials, risk of bias in non-randomised studies of interventions and methodological index for non-randomised studies. Two researchers will independently perform study selection, data extraction and risk of bias assessment, with disagreements resolved by group discussions. Subgroup analyses will be performed according to different types of treatment for AD.
Ethics approval is not required for this systematic review. Findings will be disseminated via peer-reviewed publication or conference proceedings.
CRD42021246566.
特应性皮炎（AD）是一种慢性炎症性皮肤病，皮肤微生物组失调在 AD 的发病机制中起着重要作用。近年来，已经评估了治疗对 AD 患者皮肤微生物组的影响；然而，研究结果存在争议。本系统评价将总结评估治疗对 AD 患者皮肤微生物组影响的研究。
我们将于 2021 年 11 月检索 PubMed、EMBASE、Web of Science、ClinicalTrials.gov 和中国临床试验注册中心；还将考虑其他数据来源，包括搜索特定作者和筛选纳入文章中引用的参考文献。将纳入接受治疗并报告与治疗相关的皮肤微生物组变化的 AD 患者的干预性研究。我们的主要结局包括皮肤微生物组多样性和与治疗相关的差异微生物；次要结局包括微生物功能和微生物相互作用。使用随机试验的 Cochrane 偏倚风险工具、干预的非随机研究的偏倚风险和非随机研究的方法学指数对偏倚风险进行评估。两名研究人员将独立进行研究选择、数据提取和偏倚风险评估，如果存在分歧，将通过小组讨论解决。将根据 AD 的不同治疗类型进行亚组分析。
本系统评价不需要伦理批准。研究结果将通过同行评审的出版物或会议记录进行传播。
PROSPERO 注册号：CRD42021246566。
